Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026
Actinium Pharmaceuticals' first-in-human Phase 1 study of ATNM-400, a HER3-targeted Actinium-225 radioconjugate, will be featured as a Trial in Progress ePoster at the ESMO 2026 Congress in Madrid. The study enrolls metastatic castration-resistant prostate cancer patients previously treated with an ARPI and taxane chemotherapy, using Zirconium-89 PET imaging to guide patient selection before Actinium-225 dosing every six weeks for up to four cycles. ATNM-400 targets HER3 rather than PSMA, positioning it across PSMA-positive, PSMA-low and PSMA-negative disease, including patients who progress on PSMA-directed therapy such as Novartis' Pluvicto.
Key figures
- Drug Name
- ATNM-400
- Phase Of Trial
- Phase 1
- Abstract number
- 2386eTiP
- Max treatment cycles
- 4
- Dosing interval weeks
- 6
- Actinium 225 half life days
- 10
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.